Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.

Autor: Rao X; Eli Lilly and Company, Indianapolis, Indiana., Chen Y; Eli Lilly and Company, Indianapolis, Indiana., Beyrer J; Eli Lilly and Company, Indianapolis, Indiana., Nash Smyth E; Eli Lilly and Company, Indianapolis, Indiana., Morato Guimaraes C; Eli Lilly and Company, Indianapolis, Indiana., Litchfield LM; Eli Lilly and Company, Indianapolis, Indiana., Bowman L; Eli Lilly and Company, Indianapolis, Indiana., Lawrence GW; Eli Lilly and Company, Indianapolis, Indiana., Aggarwal A; Eli Lilly and Company, Indianapolis, Indiana., Andre F; Université Paris Sud, Orsay, France.; Inserm, Gustave Roussy Cancer Campus, UMR981, Villejuif, France.; Department of Medical Oncology, Gustave Roussy, Villejuif, France.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Sep 01; Vol. 29 (17), pp. 3372-3383.

Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: systematic bias assessment of ovarian cancer treatment effectiveness.

Autor: Kuehne F; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria., Arvandi M; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria., Hess LM; Eli Lilly and Company, Indianapolis, IN, USA., Faries DE; Eli Lilly and Company, Indianapolis, IN, USA., Matteucci Gothe R; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria., Gothe H; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Chair of Health Sciences/Public Health, Medical Faculty 'Carl Gustav Carus', Technical University Dresden, Dresden, Germany., Beyrer J; Eli Lilly and Company, Indianapolis, IN, USA., Zeimet AG; Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria., Stojkov I; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria., Mühlberger N; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria., Oberaigner W; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Institute for Clinical Epidemiology, Cancer Registry Tyrol, Tirol Kliniken, Innsbruck, Austria., Marth C; Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria., Siebert U; Department of Public Health, Health Services Research and Health Technology Assessment, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT TIROL - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Center for Health Decision Science and Departments of Epidemiology and Health Policy & Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: usiebert@hsph.harvard.edu.

Publikováno v: Journal of clinical epidemiology [J Clin Epidemiol] 2022 Dec; Vol. 152, pp. 269-280. Date of Electronic Publication: 2022 Oct 15.

Can Public Welfare Provide Marital Casework Services?

Autor: Beyrer, J. Benjamin

Publikováno v: Marriage and Family Living, 1953 Feb 01. 15(1), 15-17.

Externí odkaz: https://www.jstor.org/stable/348183

A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms.

Autor: Beyrer J; Department of Value, Evidence, and Outcomes (VEO) & Global Patient Safety, Eli Lilly & Company, Indianapolis, IN 46285, USA., Abedtash H; Department of Value, Evidence, and Outcomes (VEO) & Global Patient Safety, Eli Lilly & Company, Indianapolis, IN 46285, USA., Hornbuckle K; Department of Value, Evidence, and Outcomes (VEO) & Global Patient Safety, Eli Lilly & Company, Indianapolis, IN 46285, USA., Murray JF; Department of Value, Evidence, and Outcomes (VEO) & Global Patient Safety, Eli Lilly & Company, Indianapolis, IN 46285, USA.

Publikováno v: Journal of comparative effectiveness research [J Comp Eff Res] 2022 May; Vol. 11 (7), pp. 499-511. Date of Electronic Publication: 2022 Mar 17.